Navigation Links
drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007
Date:2/6/2008

in the company's financial reporting. However, adjusted EBITDA should not be considered in isolation, or as a substitute for, or as superior to, net income/loss, cash flows, or other consolidated income/loss or cash flow data prepared in accordance with GAAP, or as a measure of the company's profitability or liquidity. Although adjusted EBITDA is frequently used as a measure of operating performance, it is not necessarily comparable to other similarly titled captions of other companies due to differences in methods of calculation. Net income/loss is the closest financial measure prepared by the company in accordance with GAAP in terms of comparability to adjusted EBITDA. A reconciliation of adjusted EBITDA to net income/loss is included with the financial statements attached to this release.

drugstore.com, inc. also uses non-GAAP measures in which CNS sales are excluded from OTC segment sales data. This non-GAAP measure is provided to enhance the user's overall understanding of the company's financial performance in the OTC segment. Management believes that these reporting metrics provide useful information to the company and to investors by excluding certain items that may not be indicative of the company's core operating results in the OTC segment. By excluding CNS sales from OTC sales data, the company can more effectively assess the buying behavior of, and the company's financial performance with respect to, its own core OTC customers (those customers making nonprescription purchases through Web sites owned by drugstore.com, inc. and its subsidiaries). However, these non-GAAP measures should not be considered in isolation, or as a substitute for, or as superior to, OTC segment sales data prepared in accordance with GAAP, or as a measure of the company's overall performance in the OTC segment. OTC segment sales measures are the closest financial measures prepared by the company in accordance with GAAP in terms of comparability to OTC segment sales measures
'/>"/>

SOURCE drugstore.com, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
2. drugstore.com, inc. to Announce Third Quarter 2007 Results During Conference Call on Monday, October 22, 2007 at 5:00 p.m. ET
3. drugstore.com and Revolution Health Group Announce Breakthrough Deal
4. TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience
5. Joint Commission International Achieves Accreditation from ISQua
6. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
7. Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue
8. Pharsight Achieves $7.3 Million in Quarterly Revenue
9. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
10. LMS integrated obstetrics solution achieves general availability
11. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...tients treated with radiation prior to surgery for...ncer recurrence and better overall survival rates,...eport examined a treatment called neoadjuvant ther...t the spread of cancer, before surgery to remove t...rapy and/or radiation. , Neoadjuvant therapy sh...
(Date:12/2/2008)...2008 - Elsevier announced today the publication of...the theme of "Second trimester abortion: women,s h...on raises complex issues regarding methods, values...ery and the sometimes complicated reality of women...ve Health Matters grew out of a conference on sec...
(Date:12/2/2008)... probably higher with aprotinin, a drug commonly u...cardiac surgery, compared with lysine analogues, a...pdf/cmaj.081109 to be published in the January 20...anada expert advisory panel will meet to decide on...in advance of the meeting. , The study, a syste...
(Date:12/2/2008)... published in the December 1, 2008, issue of Clin...ssociation for Cancer Research, show lapatinib ben...e women with HER2-negative breast cancer or those ...it. In addition, a misclassification of metastatic...revents some people from receiving optimal therapy...
Breaking Medicine News(10 mins):Health News:Elsevier announces the 2008 supplement of Reproductive Health Matters 2Health News:HER2 levels may aid in treatment selection for metastatic breast cancer 2
...ing weight by dietary changes and increased physic...condition where blood glucose// levels are higher ...ese are the results of a new study that was publis...Care, of women who participated in the Diabetes Pr...
...e being hit the most by obesity-related disorders....ne by doctors that fails to// detect these problem...ight divided by height- is used in the standard me...ing to the experts, East and South Asians were aff...
...n Canada ahead of HIV/AIDS, diabetes and car accid...inal communities. With World// Suicide Prevention ... from the Canadian Institutes of Health Research (...lenges posed by suicide, its causes and possible p...
...er a period of 30 years and has infected many peop...Recently, 3 people in Delhi// have tested positive...rs who transmit chikungunya fever to human. The N...able Diseases (NICD) tested 6 blood samples of whi...
Other Medicine News:Health News:Bladder Control following Weight loss in women with Prediabetes 2Health News:Bladder Control following Weight loss in women with Prediabetes 3Health News:Getting Serious About Suicide Prevention 2
(Date:12/2/2008)...LA, Calif., Dec. 2 TorreyPines The...positive results from a 26 patient Phase II trial ...r xerostomia, or dry mouth, in patients with Sjogr... a statistically significant increase in salivary ...oses: 10 mg, 15 mg, and 20 mg. These doses were sa...
(Date:12/2/2008)..., Ill., Dec. 2 Horizon Therapeutic...ny, today announced that two pivotal,Phase 3 tria...didate, HZT-501,met all primary endpoints. HZT-5...roduct containing ibuprofen and famotidine, demons...he incidence of non-steroidal,anti-inflammatory d...
(Date:12/2/2008)...DA, Md., Dec. 2 Micromet...any developing novel, proprietary antibodies for t...e diseases, today announced that it has entered in...ancing Facility (CEFF) with Kingsbridge Capital Li...s of the agreement, Kingsbridge has committed to p...
(Date:12/1/2008)...O, Dec. 2 New research ...t-slice computed tomography (CT) scanner in an eme...of stroke victims who receive a potentially life-s...t North Shore Medical Center (NSMC)-Salem Hospital...nnual meeting of the Radiological Society of North...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 1OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 2OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 3New technique produces genetically identical stem cells 6347 1New technique produces genetically identical stem cells 6347 2Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 1Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 2Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 3Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 4Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 5Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 1Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 2Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 3
...ta to be Presented April 15th at EASL Conference i...pril 11, 2007,/PRNewswire-FirstCall/ - MIGENIX Inc...ious diseases, has received new top-line results,c...s (November 6,2006) indicating evidence of clinic...study using the oral alpha-glucosidase,inhibitor, ...
...MBRIDGE, Mass.--(BUSINESS WIRE)--Apr 11, 2007 - Gl...d biopharmaceutical,company, announced today that ...omidepsin will be presented at the 2007,Annual Mee...h,taking place in Los Angeles, CA April 14-18, 200...preclinical research,performed by multiple academi...
Other Medicine Technology:New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 2Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 3
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Inquire
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of
Medicine Products: